MX9706689A - Tratamiento de trastornos causados por el factor de crecimiento de citocina. - Google Patents

Tratamiento de trastornos causados por el factor de crecimiento de citocina.

Info

Publication number
MX9706689A
MX9706689A MX9706689A MX9706689A MX9706689A MX 9706689 A MX9706689 A MX 9706689A MX 9706689 A MX9706689 A MX 9706689A MX 9706689 A MX9706689 A MX 9706689A MX 9706689 A MX9706689 A MX 9706689A
Authority
MX
Mexico
Prior art keywords
treatment
cytokine growth
pyridone
substituted
growth factor
Prior art date
Application number
MX9706689A
Other languages
English (en)
Inventor
Solomon B Margolin
Original Assignee
Solomon B Margolin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solomon B Margolin filed Critical Solomon B Margolin
Publication of MX9706689A publication Critical patent/MX9706689A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

En modalidades preferidas, un método para la prevencion y tratamiento de trastornos causados por proliferacion incrementada y biosíntesis incrementada causada por factores de crecimiento de citocina en humanos y otros animales, el método que incluye: administrar a un humano u otro animal una dosis efectiva de una sustancia farmacéutica que incluye una 2(1H) piridona N-sustituida y/o una 3(1H)piridona N-sustituidas; y una composicion para la prevencion y tratamiento de trastornos causados por la proliferacion incrementada y biosíntesis incrementada causadas por factores de crecimiento de citocina en humanos y otros animales; la composicion que incluye: una preparacion farmacéutica que incluye una dosis efectiva de una 2(1H)piridona N-sustituida y/o una 3(1H)piridona N-sustituida.
MX9706689A 1995-03-03 1997-09-03 Tratamiento de trastornos causados por el factor de crecimiento de citocina. MX9706689A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39796295A 1995-03-03 1995-03-03

Publications (1)

Publication Number Publication Date
MX9706689A true MX9706689A (es) 1998-06-30

Family

ID=23573420

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9706689A MX9706689A (es) 1995-03-03 1997-09-03 Tratamiento de trastornos causados por el factor de crecimiento de citocina.

Country Status (10)

Country Link
EP (1) EP0813409B1 (es)
JP (1) JPH11501911A (es)
AT (1) ATE265851T1 (es)
AU (1) AU697742B2 (es)
BR (1) BR9607541A (es)
CA (1) CA2214531C (es)
DE (1) DE69632396T2 (es)
ES (1) ES2220975T3 (es)
MX (1) MX9706689A (es)
WO (1) WO1996027374A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5716632A (en) * 1989-11-22 1998-02-10 Margolin; Solomon B. Compositions and methods for reparation and prevention of fibrotic lesions
US6114353A (en) 1995-03-03 2000-09-05 Margolin; Solomon B. Compositions and method for treatment of lymphomas, leukemias, and leiomyomas
WO1997010712A1 (en) * 1995-09-19 1997-03-27 Margolin Solomon B Inhibition of tumor necrosis factor alpha
KR19980020379A (ko) * 1996-09-09 1998-06-25 비. 마르골린 솔로몬 사이토킨 성장인자로 인한 질병의 치료방법
WO1999047140A1 (en) * 1998-03-17 1999-09-23 Margolin Solomon B Topical antiseptic compositions and methods
CA2388840C (en) * 2000-01-24 2011-09-13 Solomon B. Margolin Treatment of lymphomas, leukemias, breast carcinomas, astrocytomas, melanomas, leiomyomas, and related tumors
AU2001230605A1 (en) * 2000-02-09 2001-08-20 Shionogi And Co., Ltd. Apoptosis inhibitor
CN100358872C (zh) * 2003-11-14 2008-01-02 上海睿星基因技术有限公司 吡啶酮衍生物及其应用
EP2591784B1 (en) 2005-05-10 2016-09-14 Intermune, Inc. Pyridine-2-one-derivatives as modulators of stress-activated protein kinase system
KR101124070B1 (ko) * 2006-06-05 2012-04-12 제논 파마슈티칼스 인크. 유기 화합물
CA2726588C (en) 2008-06-03 2019-04-16 Karl Kossen Compounds and methods for treating inflammatory and fibrotic disorders
US10092552B2 (en) * 2011-01-31 2018-10-09 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
US8697753B1 (en) 2013-02-07 2014-04-15 Polichem Sa Method of treating onychomycosis
EP3126362B1 (en) 2014-04-02 2022-01-12 Intermune, Inc. Anti-fibrotic pyridinones

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4052509A (en) * 1972-12-18 1977-10-04 Affiliated Medical Research, Inc. Method for reducing serum uric acid levels
US4042699A (en) * 1972-12-18 1977-08-16 Affiliated Medical Research, Inc. Method for reducing serum glucose levels
JPH02215719A (ja) * 1989-02-15 1990-08-28 Yamauchi Akitomo 線維化病変組織の修復並びに線維化病変の阻止剤
US5310562A (en) * 1989-11-22 1994-05-10 Margolin Solomon B Composition and method for reparation and prevention of fibrotic lesions
DE69431433T2 (de) * 1993-05-07 2003-12-04 Solomon B Margolin Zusammensetzungen und verfahren zur reparatur und vorbeugung fibrotischer verletzungen

Also Published As

Publication number Publication date
AU5300596A (en) 1996-09-23
DE69632396D1 (de) 2004-06-09
AU697742B2 (en) 1998-10-15
EP0813409A1 (en) 1997-12-29
ATE265851T1 (de) 2004-05-15
BR9607541A (pt) 1997-12-23
EP0813409A4 (en) 1999-01-07
JPH11501911A (ja) 1999-02-16
CA2214531C (en) 2009-01-20
EP0813409B1 (en) 2004-05-06
DE69632396T2 (de) 2005-05-04
CA2214531A1 (en) 1996-09-12
WO1996027374A1 (en) 1996-09-12
ES2220975T3 (es) 2004-12-16

Similar Documents

Publication Publication Date Title
MX9706689A (es) Tratamiento de trastornos causados por el factor de crecimiento de citocina.
DE69634609D1 (de) Analgesiche synergie durch gleichzeitige verabreichung von subanalgesichen doseneines mu-opioidanagonisten und eines kappa - 2- opioidanagonisten
IL125282A (en) Substituted imidazole compounds, process for their preparation, pharmaceutical compositions containing them and use thereof in the preparation of medicaments for treating cytokine mediated diseases
ATE252899T1 (de) Schilddrüsenhormone enthaltende mittel
CA2068324A1 (en) Metal-peptide compositions and methods for stimulating hair growth
LTIP702A (en) A slimming pharmaceutical composition
YU47543B (sh) Postupak za dobijanje farmaceutskog preparata za stimulaciju granulocita
HUT54060A (en) Process for producing pharmaceutical compositions with antiviral or antibacterial effect
PL338982A1 (en) Drug for improving duration of muscle action or for treating muscular disorders or diseases
ZA967880B (en) Compositions and methods for inhibition of the patho-physiologic actions in mammals in tumor necrosis facto-alpha
MY125485A (en) Oral treatment of companion animals with extoparasiticidal spinosyns.
UA35611C2 (uk) Композиція місцевого застосування для інгібування росту волос у ссавців, спосіб із її використанням та композиція місцевого застосування для доставки водорозчинного фармакологічного засобу до шкіри
DK164441C (da) Anvendelse af et piperidinderivat til fremstilling af et farmaceutisk praeparat til behandling af smertetilstande
NZ510153A (en) Tan-1057 derivatives with reduced toxicity and their use in medicaments for treating bacterial infections in humans and mammals
IL88971A (en) Disubstituted pyridines, process and intermediates, their preparation and pharmaceutical compositions containing them
CA2108330A1 (en) Enhancer for the Antianemia Effect of Erythropoietin and Method of Augmenting the Antianemia Effect of Erythropoietin
EP0744176A3 (en) Methods for inhibiting bone loss
ATE316379T1 (de) Oxyhuminsäure und ihre verwendung zur behandlung von verschiedenenen störungen
BG103905A (en) New bpc peptide salts with organoprotective activity, method for their preparation and application in medicine
UA41326C2 (uk) Фармацевтична композиція для профілактики або лікування вірусних захворювань, засіб для профілактики або лікування вірусних захворювань
OA09771A (en) Asphodelus composition for increasing white blood cell count.
HUT62789A (en) Process for producing pharmaceutical composition comprising r(+)-3-amino-1-hydroxypyrroliden-2-one as active ingredient and suitable for treating anxiety
MY104932A (en) Immunomodulatory azaspiranes
GEP19971029B (en) Antiviral or antibacterial compound and method of use thereof
AU632287C (en) Pharmaceutical preparation for treatment of mastitis in animals and humans